3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
5
Gastrointestinal
4
Head & Neck
3
Sarcoma
2
Thoracic
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Endometrial Neoplasms
11
Uterine Cervical Neoplasms
5
Ovarian Neoplasms
4
Vulvar Neoplasms
3
Peritoneal Neoplasms
2
Uterine Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cervical Cancer Stage IB1
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Breast Neoplasms
1
Anus Neoplasms
1
Anastomotic Leak
1
Interventions
Paclitaxel
28
Carboplatin
28
pembrolizumab
25
Bevacizumab
14
liposomal doxorubicin
12
Cisplatin
11
Gemcitabine
10
Radiotherapy
8
Drug Therapy
8
Cyclophosphamide
8
Blood Specimen Collection
8
Topotecan
7
Nivolumab
7
olaparib
6
Doxorubicin
6
niraparib
5
Therapeutics
5
Dexamethasone
5
pertuzumab
4
pazopanib
4
lenvatinib
4
fludarabine
4
cemiplimab
4
atezolizumab
4
Trastuzumab
4
Surveys and Questionnaires
4
Psychiatric Rehabilitation
4
Polymerase Chain Reaction
4
Fulvestrant
4
Docetaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Indocyanine Green
×
Gynecologic
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled